Table 1.
Patient characteristics and genetic polymorphisms
| Total | 2677SNP | 3435SNP | P‐value 2766 | |||||
|---|---|---|---|---|---|---|---|---|
| Characteristics | n = 122 (%) | TT/TA/AA (n = 29) | GT/GA (n = 53) | GG (n = 40) | TT (n = 17) | TC (n = 54) | CC (n = 51) | / P‐value 3435 |
| Age | ||||||||
| Median (range) | 61 (34–82) | 60 (41–76) | 61 (34–82) | 60 (48–82) | 61 (45–76) | 60.5 (34–82) | 60 (41–76) | 0.352/0.789† |
| Gender | ||||||||
| Male | 105 (86.1%) | 23 (79.3%) | 46 (86.8%) | 36 (90%) | 13 (76.5%) | 47 (87.0%) | 45 (88.2%) | 0.440/0.461‡ |
| Female | 17 (13.9%) | 6 (20.7%) | 7 (13.2%) | 4 (10%) | 4 (23.5%) | 7 (13.0%) | 6 (11.8%) | |
| Pathology | ||||||||
| Adenocarcinoma | 47 (38.5%) | 7 (24.1%) | 23 (43.4%) | 17 (42.5%) | 4 (23.5%) | 23 (42.6%) | 20 (39.2%) | 0.424/0.188‡ |
| Squamous cell carcinoma | 56 (45.9%) | 15 (51.7%) | 23 (43.4%) | 18 (45.0%) | 8 (47.1%) | 23 (42.6%) | 25 (49.0%) | |
| Small cell | 9 (7.4%) | 4 (13.8%) | 4 (7.5%) | 1 (2.5%) | 4 (23.5%) | 3 (5.6%) | 2 (3.9%) | |
| Others | 10 (8.2%) | 3 (10.3%) | 3 (5.7%) | 4 (10.0%) | 1 (5.9%) | 5 (9.3%) | 4 (7.8%) | |
| Stage at diagnosis | ||||||||
| I–II | 2 (1.6%) | 0 (0.0%) | 0 (0.0%) | 2 (5.0%) | 0 (0.0%) | 0 (0.0%) | 2 (3.9%) | 0.247/0.425‡ |
| III | 45 (36.9%) | 11 (37.9%) | 23 (42.5%) | 11 (27.5%) | 7 (41.2%) | 23 (41.5%) | 15 (29.4%) | |
| IV | 75 (61.5%) | 18 (62.1%) | 30 (57.5%) | 27 (67.5%) | 10 (58.8%) | 31 (58.5%) | 34 (66.7%) | |
| Taxane | ||||||||
| Paclitaxel | 53 (43.4%) | 9 (31.0%) | 28 (52.8%) | 16 (40.0%) | 5 (29.4) | 26 (48.1%) | 22 (43.1%) | 0.272/0.564‡ |
| Paclitaxel‐albumin | 5 (4.1%) | 1 (3.4%) | 3 (5.7%) | 1 (2.5%) | 1 (5.9%) | 3 (5.6%) | 1 (2.0%) | |
| Docetaxel | 65 (52.5%) | 19 (65.5%) | 22 (41.5%) | 23 (57.5%) | 11 (64.7%) | 25 (46.3%) | 28 (54.9%) | |
| Smoking | ||||||||
| Smoker or ever smoker | 91 (74.6%) | 22 (75.9%) | 42 (79.2%) | 26 (65.0%) | 35 (68.6%) | 42 (77.8%) | 14 (82.4%) | 0.366/0.561‡ |
| Non‐smoker | 31 (25.4%) | 7 (24.1%) | 10 (18.9%) | 14 (35.0%) | 3 (17.6%) | 12 (22.2%) | 16 (31.4%) | |
†
t‐test.
‡
Pearson chi‐square.